I've wondered the same. Cyrus is a young guy - probably not a lot of experience working through these types of things, and over his head in terms of dealing with (and managing to some extent) the relationship with the FDA. There is a fine line between pushing back on something unreasonable, and bending over and saying "thank you sir, i'll have another". That's where someone who has experience and even relationships with the FDA can be important.
It's also clear that Cyrus underestimated how toxic CytoDyn's reputation had become under NP. He knew to some extent (because one of his initiatives was to change the name of the company), but the fallout was more extreme than he even realized, and there was just no way they were giving us the benefit of the doubt. at their core, the FDA is a risk averse organization.
We need a CEO who can confidently work with the FDA to basically say "look, we realize our prior leadership made mistakes, but this is a new company, with new people, and a drug that can help a lot of people." - and convince the FDA turn the page, and give us the benefit of the doubt to some extent.
It's also clear that Cyrus underestimated how toxic CytoDyn's reputation had become under NP. He knew to some extent (because one of his initiatives was to change the name of the company), but the fallout was more extreme than he even realized, and there was just no way they were giving us the benefit of the doubt. at their core, the FDA is a risk averse organization.
We need a CEO who can confidently work with the FDA to basically say "look, we realize our prior leadership made mistakes, but this is a new company, with new people, and a drug that can help a lot of people." - and convince the FDA turn the page, and give us the benefit of the doubt to some extent.
7
